Risks and Benefits of Helicobacter pylori Eradication: Current StatusReportar como inadecuado




Risks and Benefits of Helicobacter pylori Eradication: Current Status - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Canadian Journal of Gastroenterology - Volume 16 2002, Issue 1, Pages 57-62

Review

Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada

Division of Gastroenterology, Department of Medicine, McGill University, Montreal, Quebec, Canada

Division of Gastroenterology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada

Division of Gastroenterology and Nutrition, Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada

Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada

Received 12 February 2001; Accepted 23 March 2001

Copyright © 2002 Hindawi Publishing Corporation.
This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License CC BY-NC http:-creativecommons.org-licenses-by-nc-4.0-, which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.


Abstract

In patients with diseases known to be associated with Helicobacter pylori infection, such as peptic ulcer, treatment of the underlying infection is the standard of care.
However, in most major consensus management guidelines, including those published in Canada, widespread testing for H pylori infection is not recommended.
This practice is not encouraged because of insufficient evidence of cost-benefit in gastric cancer prevention, the potential for increases in antibiotic resistance and the controversial hypothesis of potential negative effects of eradication in certain clinical entities.
For example, there is insufficient evidence to recommend against eradicating H pylori discovered in a patient with symptoms of gastroesophageal reflux disease.
The management guidelines designed specifically in Canada should, therefore, continue to be applied, with H pylori diagnosed and treated in appropriately selected patients.





Autor: Richard H Hunt, Carlo Fallone, Sander Veldhuyzen van Zanten, Phil Sherman, Fiona Smaill, Alan BR Thomson, and the Canadian Helico

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados